The grades of three Mortgage stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Radian Group (NYSE:) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Radian Group provides credit-related insurance coverage and financial services to mortgage lenders and other financial institutions. In Portfolio Grader’s specific subcategory of Earnings Revisions, RDN also gets an A. .
Top 10 Managed Healthcare Stocks To Buy For 2015: Ixia(XXIA)
Ixia supplies converged network and application performance testing solutions in the United States and internationally. It designs and validates a range of Internet protocol (IP) and third generation/long-term evolution networking equipment. The company?s solutions generate realistic traffic to stress routers, switches, and converged network appliances. It provides converged IP test systems and services for wireless and wired infrastructures and services. Ixia serves network equipment manufacturers, service providers, enterprises, and government agencies. The company was founded in 1997 and is headquartered in Calabasas, California.
Advisors' Opinion:- [By Evan Niu, CFA]
What: Shares of Ixia (NASDAQ: XXIA ) got crushed today, down by 25% at the low, after the company announced preliminary results.
So what: Revenue in the second quarter is expected in the range of $114 million to $116 million, shy of Ixia's previous guidance that was calling for $119 million to $122 million. The silver lining was that revenue from recent acquisitions is expected at the high end of guidance of $28 million to $32 million.
Top 10 Managed Healthcare Stocks To Buy For 2015: Avis Budget Group Inc.(CAR)
Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, and ancillary services to businesses and consumers worldwide. It supplies rental cars to the premium commercial and leisure segments of the travel industry under the Avis brand; and to the value-conscious segments of the industry under the Budget brand. The company operates or licenses the Avis car rental system that includes approximately 5,200 locations; and operates approximately 2,100 Avis car rental locations in on-airport and local rental markets; and operates or licenses the Budget vehicle rental system comprising approximately 3,050 car rental locations, and operates approximately 1,100 Budget car rental locations. It also operates local and one-way truck rental businesses, and operates a combined fleet of approximately 26,000 trucks, which are rented through a network of approximately 1,850 dealers and 300 company-operated locations in the continental United States serving the consumer and light commercial sectors. In addition, the company engages in the sale and rental of optional products and services, including loss damage waivers; insurance products, such as additional/supplemental liability insurance or personal accident/effects insurance; automobile towing equipment and other moving accessories consisting of hand trucks, furniture pads, and moving supplies; and products for driving convenience, such as where2 GPS navigation units, optional roadside assistance, fuel service options, and electronic toll collection, as well as other ancillary products and services comprising rental of satellite radio units and child safety seats. Its rental fleet comprises approximately 393,000 vehicles. The company was formerly known as Cendant Corporation. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Rich Duprey]
Seeking to expand its car rental business into the deep-value market, Avis Budget Group (NASDAQ: CAR ) announced this morning that it's acquiring the sixth largest car rental agency, Payless Car Rental, for $50 million cash.
- [By Ben Levisohn]
Unlike other companies that have been targeted by activists–we’re looking at you Abercrombie & Fitch (ANF)–this has been a very good year for Hertz Global and its competitor Avis Budget Group (CAR). Hertz is up 73%, while Avis has more than doubled. So MKM Partners’ Christopher Agnew and Bradford Dalinka can see the logic in the “poison pill:”
- [By Brendan Byrnes]
In this video segment, Whitney draws a parallel between auto rentals today and the railroad industry a decade ago. Can consolidation and more rational competition spell good news for investors? Find out what's been going on at Hertz (NYSE: HTZ ) and Avis (NASDAQ: CAR ) and what it means to you. The�full version�of the interview can be found�here.
Top Net Payout Yield Stocks To Own Right Now: Virgin Australia Holdings Ltd (VBHLF)
Virgin Australia Holdings Limited (VAH) is an Australia-based company engaged in the development and operation of domestic and international airlines. VAH�� fleet includes ATR-72, Embraer 190, Boeing 737-700, Boeing 737-800, AIRBUS A330 and Boeing 777-300ER. It product includes Airbus A330 Business Class. During the fiscal year ended June 30, 2012, the Company carried 19,468,929 guests on 216 city pairs to 52 destinations, and operated 162,817 flights. On February 22, 2012, under the proposal, all of the shares in the international airline business of Virgin Australia were transferred to a new holding company, Virgin Australia International Holdings Pty Ltd. In April 2013, it acquired 100% of the issued share capital in Skywest Airlines Ltd. In July 2013, Virgin Australia Holdings Limited announced that it has acquired 60% interest of Tiger Airways Australia Pty Limited from Tiger Airways Holdings Limited. Advisors' Opinion:- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Australian stocks gave ground in early Friday trading, with banks broadly lower after overnight losses in the U.S., where investors worried that better-than-expected data would prompt the Federal Reserve to roll back stimulus soon. The S&P/ASX 200 (AU:XJO) lost 0.4% to 5,178.30, as National Australia Bank Ltd. (AU:NAB) (NAUBF) fell 1.8%, Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) lost 0.8%, and Macquarie Group Ltd. (AU:MQG) (MCQEF) retreated 1.3%. Among the resource shares, losses for gold both in New York and in early Asian electronic trade helped send Evolution Mining Ltd. (AU:EVN) (CAHPF) down 1.9% and Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) off 4.5%, though Newcrest Mining Ltd. (AU:NCM) (NCMGF) held the drop to 0.4%. Oil prices managed a modest gain, however, resulting in a 0.2% rise for Oil Search Ltd. (AU:OSH) (OISHF) and Karoon Gas Australia Ltd. (AU:KAR) (KRNGF) , while Woodside Petroleum Ltd. (AU:WPL)
Top 10 Managed Healthcare Stocks To Buy For 2015: Foster Wheeler AG. (FWLT)
Foster Wheeler AG, through its subsidiaries, operates as an engineering and construction contractor; and power generating equipment supplier worldwide. Its Global Engineering and Construction division designs, engineers, and constructs onshore and offshore upstream oil and gas processing facilities; natural gas liquefaction facilities and receiving terminals; gas-to-liquids facilities; and oil refining, chemical and petrochemical, pharmaceutical, and biotechnology facilities, as well as related infrastructure, including power generation, distribution, gasification, and processing facilities for metals and mining sector. This division also designs carbon capture and storage, and solid fuel-fired integrated gasification combined-cycle power plants, as well as coal-to-liquids, coal-to-chemicals, and biofuels facilities; and operates power generation facilities, such as conventional and renewable source, and waste-to-energy facilities. In addition, it offers project and constr uction management services, including procurement of equipment, materials, and services from third-party suppliers and contractors; provides environmental remediation services; and designs and supplies direct-fired furnaces comprising fired heaters and waste heat recovery generators used in refinery, chemical, petrochemical, and oil and gas processes. The company�s Global Power division designs, manufactures, and erects steam generators and auxiliary equipment, including surface condensers, feedwater heaters, coal pulverizers, steam generator coils and panels, biomass gasifiers, and replacement parts; nitrogen-oxide reduction systems and components; and flue gas desulfurization equipment for steam generators. It also offers various site services; conducts research and development in combustion, fluid and gas dynamics, heat transfer, materials, and solid mechanics areas; and licenses technology to other steam generator suppliers. The company was founded in 1894 and is based in Geneva, Switzerland.
Advisors' Opinion:- [By Dimitra DeFotis]
Engineering and construction companies like�Chicago Bridge & Iron (CBI) and Foster Wheeler (FWLT) have contracted with Rosneft and ExxonMobil (XOM) on a proposed $15 billion Russian liquefied-natural gas (LNG) project. But Russian gas giant Gazprom dominates. Research from last fall here on how�Russia has been pushing to liberalize and expand its natural gas market.�(subscription required)
- [By CRWE]
Foster Wheeler AG (Nasdaq:FWLT) reported that a subsidiary of its Global Engineering and Construction Group has been awarded a contract by PDVSA Petr贸leo S.A. for the engineering, procurement services and construction management (EPCm) for the El Palito Refinery Expansion Project in Venezuela.
Top 10 Managed Healthcare Stocks To Buy For 2015: PDL BioPharma Inc.(PDLI)
PDL BioPharma, Inc. engages in intellectual property asset management and royalty bearing assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Advisors' Opinion:- [By Brian Orelli]
PDL BioPharma (NASDAQ: PDLI ) did much better with the spin out of its development stage program into Facet Biotech. The biotech started trading at $13�per share, and was eventually taken out by Abbott for $27. The main assets now reside in Abbott's aforementioned spinout AbbVie in conjunction with Biogen Idec, which was developing the drugs with PDL. If the drugs are successful, maybe the duo will spin them out into a joint venture, completing the cycle?
- [By Selena Maranjian]
PDL BioPharma (NASDAQ: PDLI ) gained 28%, collecting royalties from a slew of medications. Its dividend yield was recently a hefty 7.6%, but investors are right to worry about its sustainability, since many of the company's revenue streams will dry up in coming years, as patents expire. Management has been seeking other revenue-generating assets and may find a new business strategy in making loans �to other medical companies.
Top 10 Managed Healthcare Stocks To Buy For 2015: Synopsys Inc (SNPS)
Synopsys, Inc., incorporated in 1986, is engaged in providing technology solutions used to develop electronics and electronic systems. It supplies the electronic design automation (EDA) software that engineers use to design, create prototypes for and test integrated circuits, also known as chips. It also supplies software and hardware used to develop the systems that incorporate integrated circuits and the software that runs on those integrated circuits. Its intellectual property (IP) products are pre-designed circuits that engineers use as components of larger chip designs rather than redesigning those circuits themselves. It also provides technical services to support its solutions and it help its customers develop chips and electronic systems. Its products and services are organized into four groups: Core EDA (which includes the Galaxy Design Platform, the Discovery Verification Platform and its Field Programmable Gate Array (FPGA) design products); IP and System-Level Solutions; Manufacturing Solutions and Professional Services. In July 2012, it acquired Ciranova. In October 2012, it acquired EVE. On November 30, 2012, the Company acquired SpringSoft. In February 2014, Synopsys Inc completed the acquisition of Target Compiler Technologies.
On September 2, 2010, the Company acquired Virage Logic Corporation. In October 2010, the Company acquired Optical Research Associates. In September 2011, the Company acquired nSys Design Systems Private Limited (nSys). In October 2011, the Company acquired Extreme DA. In January 2012, the Company acquired ExpertIO, Inc. In February 2012, the Company acquired Magma Design Automation Inc.
Core EDA products
The Company offers a number of Core EDA products to address the process. Its Core EDA products fall into the suites, which included the Galaxy Design Platform, which includes tools to design an integrated circuit; the Discovery Verification Platform, which includes tools to verify that an integrated circuit behaves! as intended, and the FPGA design products. Its Galaxy Design Platform provides its customers with a single, integrated chip design solution, which includes individual products and incorporates common libraries and consistent timing, delay calculation and constraints throughout the design process. The platform allows designers the flexibility to integrate internally-developed and third-party tools. With this advanced functionality, common foundation and flexibility, its Galaxy Design Platform reduces design times; decrease integration costs and minimize the risks inherent in advanced, integrated circuit designs. Its products span both digital and analog/mixed-signal designs.
The products included in the Galaxy Design Platform are the IC Compiler physical design solution, Design Compiler logic synthesis product, Galaxy Custom Designer physical design solution for analog/mixed-signal designs, PrimeTime/PrimeTime SI timing analysis products, StarRC product for extraction, and the Hercules and IC Validator physical verification product family. The Lynx Design System is a production-ready chip implementation environment that combines a Galaxy-based design flow, graphical user interface (GUI)-based runtime automation, design metrics capture and reporting, and utilities that automate the configuration of pre-validated foundry data. The Lynx Design System helps customers improve their productivity and optimally deploy Synopsys tools and methodologies.
The Company�� Discovery Verification Platform is an integrated portfolio of functional, analog/mixed-signal, formal and low-power verification products. The platform includes its simulation and verification products and design-for-verification methodologies, and provides a consistent control environment to help improve the speed, breadth and accuracy of its customers��verification efforts. The Discovery Verification Platform�� components support industry standards and span both digital and analog/mixed-signal designs. The principa! l product! s included in the Discovery Verification Platform are the VCS comprehensive RTL verification solution, Formality formal verification sign-off solution, NanoSim FastSPICE circuit simulation and analysis product, high-speed interface module (HSIM) hierarchical FastSPICE circuit simulation and analysis product, HSPICE circuit simulator, and CustomSim circuit simulation solution. FPGAs are chips that can be customized or programmed to perform a specific function after they are manufactured.
Intellectual Property (IP) and System-Level Solutions
Synopsys is a provider of high-quality, silicon-proven IP solutions for system-on-chip (SoC) designs. The broad DesignWare IP portfolio includes high quality solutions for widely used interfaces such as universal serial bus (USB), PCI Express, double data rate (DDR), Ethernet, serial advanced technology attachment (SATA) and high-definition multimedia interface (HDMI). In addition, Synopsys offers analog IP for high-definition video, analog-to-digital data conversion and audio. With its recent acquisition of Virage Logic Corporation, we added embedded memories, including static random access memory (SRAMs) and non-volatile memory, logic libraries, embedded test and repair IP and configurable processor cores, to its IP portfolio.
Synopsys has a portfolio of tools, models and services for the system-level design of SoCs. Primary system-level products include Platform Architect for architectural optimization, SPW and System Studio for algorithm design, Processor Designer for custom processor design, and Synphony Model and C Compiler for High Level Synthesis. In addition to these tools for the system-level design of SoCs, its portfolio includes prototyping tools for hardware verification, software development and hardware-software integration. With FPGA-based prototyping systems (HAPS), designers can speed embedded software development by three to six months with near real runtime speeds and real world interfaces, such as its pre-t! ested Des! ignWare IP components. The HAPS hardware systems are a modular, scalable and accurate way to model a chip. Its virtual prototyping solutions enable software engineers to start SoC and application software up to twelve months before traditional methods.
Manufacturing Solutions
The Company�� Manufacturing Solutions products and technologies address this problem by introducing manufacturability and yield considerations early in the design process, thereby improving yields. Some of its Manufacturing Solutions address mask-making and yield enhancement of very small-geometry integrated circuits, as well as high-level modeling of physical effects within the integrated circuit. Its Manufacturing Solutions include the Technology-CAD (TCAD) device modeling products, Proteus OPC optical proximity correction (OPC) products, CATS mask data preparation product and yield management solutions, including odyssey and recipe manager and editor (RME), and yield explorer.
Professional Services and Training
Synopsys provides consulting and design services that address all phases of the SoC development process. These services assist Synopsys customers with new tool and methodology adoption, chip architecture and specification development, functional and low power design and verification, and physical implementation and signoff. It also provides a range of expert training and workshops on its latest tools and methodologies.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Synopsys (Nasdaq: SNPS ) , whose recent revenue and earnings are plotted below. - [By Anna Prior]
Synopsys Inc.'s(SNPS) fiscal fourth-quarter profit nearly doubled on a top-line increase driven by growth in the company’s time-based license revenue. However, the company’s guidance for the current quarter came in below Wall Street expectations.
Top 10 Managed Healthcare Stocks To Buy For 2015: MEDIWARE Information Systems Inc.(MEDW)
Mediware Information Systems, Inc., together with its subsidiaries, engages in the design, development, and marketing of software solutions targeting specific processes within healthcare institutions. The company offers software systems consisting of company's proprietary application software, and third-party licensed software and hardware. It licenses, implements, and supports clinical and performance management, blood donor, and blood and biologic management products in the United States; and medication management solutions in the United States, the United Kingdom, Ireland, and South Africa. The company?s blood and biologics management solutions include HCLL Transfusion and HCLL Donor, which address blood donor recruitment, blood processing, and transfusion activities for hospitals and medical centers; BloodSafe suite of hardware and software that enable healthcare facilities to store, monitor, distribute, and track blood products; LifeTrak software for blood centers; a nd BiologiCare, a bone, tissue, and cellular product tracking software. Its medication management products comprise WORx, a pharmacy information system to manage inpatient and outpatient pharmacy operations; MediCOE, a physician order entry module; MediMAR, a nurse point-of-care administration and bedside documentation module; MediREC, which assists in achieving compliance with a Joint Commission mandate; and pharmacy management and electronic prescribing systems. The company?s performance management products include InSight software that tracks performance metrics to assist healthcare managers to manage performance. It also provides software installation and maintenance services, as well as billing and collection services to home infusion and home/durable medical equipment markets. The company markets its products primarily through its direct sales force. Mediware Information Systems, Inc. was founded in 1970 and is headquartered in Lenexa, Kansas.
Advisors' Opinion:- [By CRWE]
Mediware Information Systems, Inc. (Nasdaq:MEDW) plans to acquire the assets of Indianapolis-based Strategic Healthcare Group LLC (SHG), a leading provider of blood management consulting, education and informatics solutions.
Top 10 Managed Healthcare Stocks To Buy For 2015: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Meg Tirrell]
Salix Pharmaceuticals Ltd. (SLXP), a maker of drugs for gastrointestinal diseases, said it will acquire Santarus Inc. (SNTS) for about $2.6 billion to gain treatments for diabetes and heartburn.
- [By Paul Ausick]
Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.
- [By Eric Volkman]
McGraw-Hill Financial's S&P Dow Jones Indices is making several adjustments to a pair of its signature products. On July 30 after market close, the S&P MidCap 400 will be the new home of Salix Pharmaceuticals (NASDAQ: SLXP ) , which advances from the S&P SmallCap 600 to replace Gardner Denver (NYSE: GDI ) . The latter company agreed to be acquired by KKR earlier this month.
Top 10 Managed Healthcare Stocks To Buy For 2015: Santa Fe Gold Corp (SFEG)
Santa Fe Gold Corporation (Santa Fe), incorporated in August 1991, is a mining company. As of June 30, 2012, the Company had four projects: its Summit silver-gold and Ortiz gold projects located in New Mexico, and its Black Canyon mica and Planet micaceous iron oxide projects located in Arizona. The Company has constructed a mill and are developing an underground mine at its Summit silver-gold project. Santa Fe�� Summit operations in southwestern New Mexico are conducted through its wholly owned subsidiary, The Lordsburg Mining Company. Its mica operations in Arizona are conducted through its wholly owned subsidiary, Azco Mica Inc. Santa Fe�� activity in Mexico is conducted through its wholly owned subsidiary, Minera Sandia, S.A. de C.V.
Summit Silver-Gold Project
The Summit silver-gold project includes the underground Summit silver-gold mine and related property consisting of 117 acres of patented mining claims and 740 acres of unpatented mining claims in Grant County, southwestern New Mexico, and the Banner mill, including mineral processing equipment consisting of a crushing and screening plant, a ball mill and a 400 ton-per-day flotation plant, and related property consisting of approximately 1,500 acres of wholly owned and leased patented and unpatented mining claims, located approximately 57 miles south of the Summit mine near Lordsburg, Hidalgo County, New Mexico. It owns and operates the Summit project under the Lordsburg Mining Company, a wholly-owned subsidiary. The Summit silver-gold property is located in Grant County, southwestern New Mexico, near the Arizona state line. The Banner mill site lies 57 miles to the south of the Summit property near the town of Lordsburg, Hidalgo County, New Mexico.
Santa Fe�� holdings at the Summit silver-gold property in Grant County, New Mexico consist of 10 patented federal mining claims totaling approximately 117 acres and 62 unpatented federal mining claims totaling approximately 740 acres. Its holdings at an! d adjacent to the Banner mill site in Hidalgo County, New Mexico consists of 86 wholly owned patented federal mining claims, 16 wholly owned unpatented mining claims, 17 leased patented mining claims and 6 leased unpatented mining claims, aggregating approximately 1,500 acres. All wholly owned claims are held in the name of Lordsburg Mining.
Ortiz Gold Project
The Ortiz Mine Grant, over which the Company holds a lease on the mineral estate underlying 42,297 acres (66 square miles) of segregated surface estate, is located 30 miles by road northeast of Albuquerque, Santa Fe County, New Mexico.
The Ortiz Mine Grant is underlain by mid-Tertiary monzonite and latite porphyry stocks, plugs, dikes and sills that have intruded Paleozoic to early-Tertiary sedimentary rocks. The intrusive rocks are part of the Ortiz Porphyry Belt, which comprises from north to south, the Cerrillos Hills, the Ortiz Mountains, the San Pedro Mountains, and South Mountain.
Black Canyon Mica Project
The Black Canyon mine is located 30 miles north of Phoenix, Arizona, and 3.5 miles west-southwest of Black Canyon City. The Glendale processing plant was located in an industrial area on the west side of Phoenix, Arizona, 47 miles to the south of the mine site. Its property holdings at and around the Black Canyon mine consists of 67 federal unpatented mining claims in Yavapai County, Arizona and nine federal unpatented mill site claims in Maricopa County, Arizona, which in total cover approximately 1,385 acres.
Planet Micaceous Iron Oxide (MIO) Project
The Planet property consists of thirty-one patented mining claims totaling 523 acres located in western Arizona. The Planet property is located in the northwest corner of La Paz County, west central Arizona. The property consists of thirty-one patented mining claims totaling 523 acres, consisting of an area of 3,600 feet wide by 8,000 feet long.
Lordsburg Exploration Project
T! he Compan! y in the the Lordsburg (Virginia) Mining District controls approximately 1,500 acres of prospective ground, the majority of which is comprised of patented mining claims that it owns, and the remainder patented and unpatented mining claims that it leases. As of June 30, 2012, the Company had completed an aerial mapping survey covering 30 square miles, carried out data compilation, conducted detailed geologic mapping and sampling, and conducted a geophysical survey.
Advisors' Opinion:- [By CRWE]
Today, SFEG remains (0.00%) +0.000 at $.139 with�31,100 shares in play thus far (ref. google finance Delayed: 11:35AM EDT July 10, 2013).
Santa Fe Gold Corporation previously reported it will receive an additional A$2.0 million from International Goldfields Limited (ASX: IGS), by way of a secured convertible note, increasing IGS��investment in Santa Fe to A$6.0 million. The funds will be used for working capital in support of improvement to mining operations.
In conjunction with the IGS financing, Santa Fe is exploring a listing on the Singapore Catalist Stock Exchange (SGX-ST). Pierce Carson, CEO of Santa Fe said, ��ith the assistance of IGS and our Singapore-based financial advisor, we have formulated a clear strategy to improve our balance sheet, bring the Summit gold-silver mine into full project performance, refinance our senior secured debt and enhance Santa Fe�� trading market for our stockholders.��/p>
- [By CRWE]
Today, SFEG has shed (-0.32%) down -0.001 at $.154 with�50,738 shares in play thus far (ref. google finance Delayed: 11:43AM EDT July 12, 2013), but don�� let this get you down.
Santa Fe Gold Corporation previously reported it has amended the Mogollon option agreement with Columbus Exploration Corporation (CLX-TSX-V) (formerly Columbus Silver Corporation) under which Santa Fe may earn 100% interest in the Mogollon Project, Catron County, New Mexico. The Mogollon Project encompasses most of the Mogollon district in southwest New Mexico, which has substantial recorded historical production of silver and gold. The project fits Santa Fe�� strategic objective of developing new ore sources to augment ore currently processed though its Lordsburg flotation mill.
- [By CRWE]
Today, SFEG surged (+7.35%) up +0.009 at $.130 with 62,550 shares in play thus far (ref. google finance Delayed: 11:32AM EDT July 11, 2013).
Santa Fe Gold Corporation previously reported its Annual Stockholder Meeting is scheduled to be held at 10:00 a.m. Mountain Time on Tuesday, August 6, 2013, at the Albuquerque Marriott Hotel located at 2101 Louisiana Blvd NE, Albuquerque, NM 87110. Santa Fe Gold Corporation is a gold and silver producer with operations in New Mexico. Its Summit mine achieved commercial production in 2012. Summit produces high value gold-silver concentrates and silica flux products that are sold under contract to domestic and overseas smelters.
- [By CRWE]
Today, SFEG surged (+8.33%) up +0.010 at $.130 with 166,303 shares in play thus far (ref. google finance Delayed: 11:59AM EDT July 8, 2013).
Santa Fe Gold Corporation previously reported its Annual Stockholder Meeting is scheduled to be held at 10:00 a.m. Mountain Time on Tuesday, August 6, 2013, at the Albuquerque Marriott Hotel located at 2101 Louisiana Blvd NE, Albuquerque, NM 87110. Santa Fe Gold Corporation is a gold and silver producer with operations in New Mexico. Its Summit mine achieved commercial production in 2012. Summit produces high value gold-silver concentrates and silica flux products that are sold under contract to domestic and overseas smelters.
Top 10 Managed Healthcare Stocks To Buy For 2015: iShares Mortgage Real Estate Capped ETF (REM)
iShares FTSE NAREIT Mortgage REITs Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the FTSE NAREIT Mortgage REITs Index (the Index). The Index measures the performance of the residential and commercial mortgage real estate sector of the United States equity market.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Peter F. Way]
An ETF of the mREITs exists, the iShares Mortgage Real Estate Capped (REM). For comparison, its past two-year price history is contrasted with the general market (SPY) and another income alternative the iShares US Preferred Stock ETF (PFF).
- [By Dan Caplinger]
But you can see in several places the consequences of the stampede toward high yield. Here are just a few:
Closed-end funds Cornerstone Progressive (NYSEMKT: CFP ) and Pimco High Income (NYSE: PHK ) both make fixed payments back to fund shareholders on a monthly basis, and their distribution yields are truly extraordinary, at about 17% and 12%, respectively. Those dividends have enticed shareholders to pay $1.30 to $1.40 or more for each $1 of assets in the funds. Yet during most months, a substantial portion of those distribution payments has simply been a return of investor capital rather than true income from the funds' investments. A recent study discussed in The Wall Street Journal found that returns on a portfolio with a combined value and dividend-income strategy outperformed a strategy focused more exclusively on maximizing dividends by an average of 1.7 percentage points per year, a huge edge in long-run returns. In the dividend ETF arena, most funds tend to focus on maximizing yield. Although the popular Vanguard Dividend Appreciation (NYSEMKT: VIG ) ETF bucks the trend by screening first for consistent dividend growth and only then looking at yield as a factor, many rival ETFs start with high-yielding stocks as their baseline and only then consider other desirable traits. Others focus solely on high-dividend niches of the market, such as iShares FTSE NAREIT Mortgage-Plus (NYSEMKT: REM ) and its concentration on high-yield mortgage REITs.When dividend stocks get too popular, their prices get out of line with both their dividend income and the fundamentals of the businesses that underlie those stocks. In simpler terms, when dividend stocks become bad values, it's time to consider looking elsewhere for a margin of safety.
- [By Doug Fabian]
The iShares Mortgage Real Estate Capped (REM) is an ETF that contains a basket of the biggest and best mortgage REITs on the market today.
This fund is pegged to the FTSE NAREIT All Mortgage Capped Index, a benchmark measure that includes top names in the space such as Annaly Capital (NLY), American Capital Agency Corp. (AGNC), Starwood Property Trust (STWD) and Two Harbors Investment Corp. (TWO).
- [By Charles Sizemore]
So, I repeat: use the recent yield spike as an opportunity to scoop up your favorite income investments. If you want to take a modest risk, follow Gundlach�� advice and accumulate mortgage REITs. Your easiest one-stop shop during the market’s taper tantrum would be the iShares Mortgage Real Estate ETF (REM).
No comments:
Post a Comment